孕三烯酮+米非司酮治疗子宫内膜异位症合并不孕的效果和安全性分析

王小娇

[关键词] 子宫内膜异位症;孕三烯酮;米非司酮;受孕率

[中图分类号] R711.71          [文献标识码] B          [文章编号] 1673-9701（2021）20-0070-03

Analysis of the effect and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility

WANG Xiaojiao

Department of Gynecology， the First People′s Hospital of Aksu Prefecture in Xinjiang， Aksu   843000， China

[Abstract] Objective To analyze the efficacy and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility. Methods 104 patients with endometriosis and infertility who were admitted to our hospital from January 2017 to March 2019 were selected as the subjects of the study. The patients were divided into the treatment group and the control group using a digital randomization method. The control group was treated with gestrinone alone， and the treatment group was treated with gestrinone and mifepristone. The clinical efficacy， changes in various clinical indicators， pregnancy rate， and adverse reactions in the two groups were observed. Results the levels of progesterone， estradiol， and luteinizing hormone in the treatment group were better than those in the control group after treatment. The endometrial thickness of the treatment group after treatment was lower than that of the control group. The endometrial thickness of the treatment group was lower than that of the control group after treatment， and the difference between the groups was significant （P<0.05）. The total clinical effective rate obtained in the treatment group was higher than that in the control group， and the difference between the groups was significant （P<0.05）. During the follow-up period， the treatment group's pregnancy rate was higher than that in the control group， and the difference between the groups was significant （P<0.05）. The pregnancy rate of the treatment group was higher. There was no statistical difference in the incidence of adverse drug reactions between the two groups （P>0.05）. Conclusion Clinical drug application （gestrinone+ mifepristone） significantly improves the effect in treating endometriosis with infertility and increases the pregnancy rate.

[Key words] Endometriosis; Gestrinone; Mifepristone; Pregency rate

子宮内膜异位症（EMS）在妇科临床较为常见，疾病发生会引起多种症状，病情严重或发展还能导致不孕，对患者身心健康都极为不利[1-2]。药物治疗是此类患者常选择的治疗方法，合理、安全的用药方案选择，保障治疗安全性的前提下帮助患者有效控制病情、提高受孕率，是临床人员关注的重点[3-4]。子宫内膜异位症属于一种雌激素依赖性疾病，患者常伴有不孕，临床治疗中应用避孕药、睾酮类衍生物等，虽有一定的治疗效果，但是长期用药会影响肝肾功能，造成损伤等[5-6]。孕三烯酮具有较强的抗雌激素和抗孕激素作用，能有效抑制卵巢分泌功能，使异位内膜萎缩;米司非酮是一种合成甾体类激素，能抑制排卵，促使子宫内膜萎缩，已广泛应用于子宫肌瘤、功能性出血等疾病的治疗中[7-8]。本文主要研究分析子宫内膜异位症合并不孕，临床应用孕三烯酮+米非司酮治疗的效果和安全性，现报道如下。